Basilea Shares Drop as Zevtera Approval Is Delayed

Shares of Basilea Pharmaceutica dropped after the Swiss drugmaker saw approval for a skin-infection drug delayed, and the company filed an arbitration claim against Johnson & Johnson.
MarketWatch